CD8A and melanoma: A similar association between CD8+ TIL numbers and response to treatment has been reported in patients with melanoma and colorectal cancer treated with pembrolizumab151,152 or atezolizumab.140 By contrast, two independent studies have reported that CD8+ TIL densities are not associated with response to anti-PD-1 in metastatic RCC.140,153